NEW YORK ( TheStreet) -- Ship Finance International (NYSE: SFL) hit a new 52-week low Monday as it is currently trading at $9.18, below its previous 52-week low of $9.20 with 328,345 shares traded as of 11:15 a.m. ET. Average volume has been 596,600 shares over the past 30 days.

Ship Finance International has a market cap of $774.6 million and is part of the services sector and transportation industry. Shares are down 55.6% year to date as of the close of trading on Friday.

Ship Finance International Limited, through its subsidiaries, engages in the ownership and operation of vessels and offshore related assets in Bermuda, Cyprus, Malta, Liberia, Norway, the United States, Singapore, the United Kingdom, and the Marshall Islands. The company has a P/E ratio of 5.9, below the average transportation industry P/E ratio of 7.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Ship Finance International as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally poor debt management. You can view the full Ship Finance International Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

Seadrill Secures New Cash as Part of Chapter 11 Filing

Seadrill Secures New Cash as Part of Chapter 11 Filing

One Reason Why Ship Finance (SFL) Stock Is Continuing to Slump Today

One Reason Why Ship Finance (SFL) Stock Is Continuing to Slump Today

3 Hold-Rated Dividend Stocks: SFL, MPLX, CF

3 Hold-Rated Dividend Stocks: SFL, MPLX, CF

'Mad Money' Lightning Round: Take Allergan Over Teva

'Mad Money' Lightning Round: Take Allergan Over Teva